09743827

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1613sxw

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	No connect hour charges in WPIFV until May 1, 2004
NEWS	12	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS	13	APR 26	PROMT: New display field available
NEWS	14	APR 26	IFIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS	15	APR 26	LITALERT now available on STN
NEWS	16	APR 27	NLDB: New search and display fields available

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:52:00 ON 30 APR 2004

```
=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 09:52:12 ON 30 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   28 APR 2004  HIGHEST RN 677701-51-8
DICTIONARY FILE UPDATES:  28 APR 2004  HIGHEST RN 677701-51-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\09743827b.str

L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1                STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 09:52:28 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      3 TO ITERATE

100.0% PROCESSED       3 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            3 TO      163
PROJECTED ANSWERS:               1 TO       80

L2            1 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 09:52:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     85 TO ITERATE

100.0% PROCESSED      85 ITERATIONS                               34 ANSWERS
SEARCH TIME: 00.00.01

L3           34 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   155.42     155.63

FILE 'CAPLUS' ENTERED AT 09:52:35 ON 30 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 30 Apr 2004  VOL 140 ISS 19
FILE LAST UPDATED: 29 Apr 2004  (20040429/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l3 full
L4            4 L3

=> d l4 1-4 ibib abs hitstr

L4   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2002:105791  CAPLUS
```

09743827

DOCUMENT NUMBER: 136:118602
TITLE: Preparation of arteannuin derivatives containing azacyclic radical
INVENTOR(S): Li, Ying; Liao, Xibin
PATENT ASSIGNEE(S): Shanghai Inst. of Pharmaceutics, Chinese Academy of Sciences, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 15 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1296009	A	20010523	CN 1999-124012	19991112
CN 1105722	B	20030416		

PRIORITY APPLN. INFO.: CN 1999-124012 19991112
OTHER SOURCE(S): CASREACT 136:118602; MARPAT 136:118602
GI





AB Compds. I, II, III (Het = triazole, benzotriazole, benzimidazole, indole, or their derivs. substituted by carboxyl, ester group, acyl, alkoxy, C1-3 alkyl, hydroxy, or hydroxymethyl; X = -OCO-, -OCH2-, -OCH2CH2-, -OCH2CH(OH)CH2-) are claimed. Title compound were synthesized by the condensation of either acetyldihydroarteannuin or (trichloroacetyl)dihydroarteannuin or methylenearteannuin or dihydroarteannuin or arteannuin 2-bromoethyl ether or arteannuin 2,3-epoxypropyl ether with nitrogen heterocyclic compound in the presence of acidic catalyst or alkaline compds or DCC, giving product with 12% to 61%

yield. Thus, dihydroarteannuin dissolved in methylenechloride, adding trifluoroacetic acid anhydrate, reacted under 0-5°, forming dihydroarteannuin trifluoroacetate, adding 1,2,4-triazole, using the TLC follow the reaction, after the workup, giving the triazole substituted dihydroarteannuin, with yield 12-20%. Title compds. are of antimalarial, antitumor, immunoregulatory, and anti-inflammatory activity.

IT **390800-25-6P 390800-26-7P 390800-31-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn of arteannuin derivative containing azacyclic group)

RN 390800-25-6 CAPLUS
CN 1H-1,2,4-Triazole, 1-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 390800-26-7 CAPLUS
CN 4H-1,2,4-Triazole, 4-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 390800-31-4 CAPLUS
CN 2H-Benzotriazole, 2-[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]- (9CI)

(CA INDEX NAME)

Absolute stereochemistry.



IT **390800-24-5P 390800-27-8P 390800-28-9P**
390800-29-0P 390800-30-3P 390800-32-5P
390800-33-6P 390800-34-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn of arteannuin derivative containing azacyclic group)

RN 390800-24-5 CAPLUS

CN 1H-1,2,4-Triazole, 1-[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 390800-27-8 CAPLUS

CN 1H-Benzimidazole, 1-[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 390800-28-9 CAPLUS
CN 1H-Benzimidazole, 1-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 390800-29-0 CAPLUS
CN 1H-Benzotriazole, 1-[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 390800-30-3 CAPLUS
CN 1H-Benzotriazole, 1-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 390800-32-5 CAPLUS
CN 1H-Benzotriazole-6-carboxylic acid, 1-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 390800-33-6 CAPLUS
CN 1H-Benzotriazole-6-carboxylic acid, 1-[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 390800-34-7 CAPLUS
CN 1H-Benzotriazole, 1-[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-6-methyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:68461 CAPLUS
DOCUMENT NUMBER: 132:108120
TITLE: Preparation of artemisinin derivatives for use as antitumor agents
INVENTOR(S): Haynes, Richard Kingston; Chan, Ho-Wai; Lam, Wai-Lun; Tsang, Hing-Wo; Hsiao, Wen-Luan
PATENT ASSIGNEE(S): Hong Kong University of Science and Technology, Peop. Rep. China; Wallace, Sheila Jane
SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000004026	A1	20000127	WO 1999-GB2276	19990714
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9949224	A1	20000207	AU 1999-49224	19990714
EP 1095043	A1	20010502	EP 1999-933049	19990714
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6649647	B1	20031118	US 2002-743860	20020415

PRIORITY APPLN. INFO.: EP 1998-305593 A 19980714
EP 1998-308283 A 19981012
WO 1999-GB2276 W 19990714

OTHER SOURCE(S): MARPAT 132:108120
GI



I



II

AB Artemisinin derivs. I [X = H, amino, alkyl, aryl; Y = H, OH, oxo, halogen, aryl, cycloalkyl, heteroaryl, amino, acyl, aryloxy, etc.; Z = O, imino], which containing a trioxane moiety and have cancer cell cytotoxicity, were prepared for use in the treatment of cancer. Some of these compds. comprise a ligand which is capable of binding to a nucleic acid and a group containing a trioxane moiety which is capable of acting as source of free radicals which are capable of chemical interacting with a nucleic acid. Thus, II was prepared in 50.5% yield by fluorination of 10ξ-dihydroartemisinin using diethylaminosulfur trifluoride (DAST) in CH2Cl2. The prepared compds. were tested for cytotoxicity against R6 and R6T24 cancer cell lines.

IT **255730-17-7P 255730-31-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of artemisinin derivs. for use as antitumor agents)

RN 255730-17-7 CAPLUS

CN Thiomorpholine, 4-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 255730-31-5 CAPLUS

CN Piperazine, 1-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **255730-18-8P 255730-33-7P 255730-47-3P**
255730-49-5P 255730-50-8P 255730-58-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of artemisinin derivs. for use as antitumor agents)

RN 255730-18-8 CAPLUS

CN Thiomorpholine, 4-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 255730-33-7 CAPLUS

CN Piperazinium, 4-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-1-methyl-1-(phenylmethyl)-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 255730-47-3 CAPLUS
CN Morpholine, 4-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 255730-49-5 CAPLUS
CN 1H-Indole, 1-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 255730-50-8 CAPLUS
CN Isoquinoline, 2-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 255730-58-6 CAPLUS
CN Piperazine, 1-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:68459 CAPLUS
DOCUMENT NUMBER: 132:122783
TITLE: synthesis and antiparasitic activity of artemisinin derivatives (endoperoxides)
INVENTOR(S): Haynes, Richard Kingston; Chan, Ho-Wai; Lam, Wai-Lun; Tsang, Hing-Wo; Cheung, Man-Ki
PATENT ASSIGNEE(S): The Hong Kong University of Science & Technology, Peop. Rep. China
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000004024	A1	20000127	WO 1999-GB2267	19990714
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2337119	AA	20000127	CA 1999-2337119	19990714
AU 9949218	A1	20000207	AU 1999-49218	19990714
AU 765860	B2	20031002		
BR 9912810	A	20010502	BR 1999-12810	19990714
EP 1095042	A1	20010502	EP 1999-933043	19990714
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
JP 2002520416	T2	20020709	JP 2000-560130	19990714
NZ 509324	A	20030725	NZ 1999-509324	19990714
CN 1122035	B	20030924	CN 1999-810650	19990714
BG 105137	A	20010831	BG 2001-105137	20010110

NO 2001000223 A 20010312 NO 2001-223 20010112
PRIORITY APPLN. INFO.: EP 1998-305596 A 19980714
WO 1999-GB2267 W 19990714
OTHER SOURCE(S): MARPAT 132:122783
GI



I

AB Synthesis of C10 substituted derivs. of artemisinin (I) [Y = halogen, (un)substituted cycloalkyl, (un)substituted aryl, (un)substituted C-linked heteroaryl, (un)substituted heterocyclylalkyl, NR1R2; R1 = H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl; R2 = (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted aryl, (un)substituted araalkyl; R1R2 together with the N form (un)substituted heterocycle] or a salt thereof is disclosed. Thus, I (Y = βPh) (II) is prepared by reaction of 10-(trimethylsiloxy)dihydroartemisinin with phenylmagnesium bromide and shows good in vitro activity against chloroquinone resistant strains. I are particularly effective in the treatment of malaria, neosporosis and coccidiosis.

IT **255730-17-7P 255730-31-5P**
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(synthesis and antiparasitic activity of artemisinin derivs. (endoperoxides))

RN 255730-17-7 CAPLUS

CN Thiomorpholine, 4-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 255730-31-5 CAPLUS
CN Piperazine, 1-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-4-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **255730-18-8P 255730-33-7P 255730-47-3P**
255730-49-5P 255730-50-8P 255730-58-6P
255912-96-0P 255912-97-1P 255912-98-2P
255912-99-3P 255913-00-9P 255913-02-1P
255913-03-2P 255913-04-3P 255913-05-4P
255913-06-5P 255913-07-6P 255913-08-7P
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and antiparasitic activity of artemisinin derivs. (endoperoxides))
RN 255730-18-8 CAPLUS
CN Thiomorpholine, 4-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 255730-33-7 CAPLUS
CN Piperazinium, 4-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-1-methyl-1-(phenylmethyl)-, iodide (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● I^-

RN 255730-47-3 CAPLUS
CN Morpholine, 4-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 255730-49-5 CAPLUS
CN 1H-Indole, 1-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-2,3-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 255730-50-8 CAPLUS
CN Isoquinoline, 2-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 255730-58-6 CAPLUS
CN Piperazine, 1-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 255912-96-0 CAPLUS
CN Piperazine, 1-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 255912-97-1 CAPLUS
CN Piperazine, 1-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-4-(2-methoxyphenyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 255912-98-2 CAPLUS
CN Piperazine, 1-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-4-(4-fluorophenyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 255912-99-3 CAPLUS
CN Piperazine, 1-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-4-(2-pyridinyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 255913-00-9 CAPLUS
CN Piperazine, 1-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 255913-02-1 CAPLUS
CN Pyrimidine, 2-[4-[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 255913-03-2 CAPLUS
CN Piperazine, 1-(4-chlorophenyl)-4-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 255913-04-3 CAPLUS
CN Piperazine, 1-(3-chlorophenyl)-4-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 255913-05-4 CAPLUS
CN Piperazine, 1-(2-chlorophenyl)-4-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 255913-06-5 CAPLUS
CN Piperazine, 1-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-4-(4-methoxyphenyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 255913-07-6 CAPLUS
CN Piperazine, 1-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-4-(2-methylphenyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 255913-08-7 CAPLUS
CN Piperidine, 1-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]-4-(phenylmethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:234337 CAPLUS
DOCUMENT NUMBER: 130:267461
TITLE: Preparation of artemisin derivative containing phenyl and heterocyclic radicals
INVENTOR(S): Li, Yang; Yang, Yonghua; Liang, Jie; Shan, Feng; Wu, Guangshao
PATENT ASSIGNEE(S): Shanghai Inst. of Materia Medica, Chinese Academy of Sciences, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 17 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent

09743827

LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1122806	A	19960522	CN 1994-113982	19941109
CN 1049435	B	20000216		

PRIORITY APPLN. INFO.: CN 1994-113982 19941109
OTHER SOURCE(S): CASREACT 130:267461; MARPAT 130:267461
GI



I

AB Title artemisin derivs. [I; X = O, NH; R = Ph, R3 substituted Ph, 2 same or different R3 and R4 substituted Ph, the heterocyclic radical is alkali adenyl, thymine, cytimidine, uracil, and their R3 substituted groups, triazo-, and CONH2 or R3 substituted triazo-; R3 = R4 = hydroxy, alkoxy (C1-C4), alkyl (C1-C4), COOCH3, COOC2H5, NHCOCH3, nitro, halogen (F, Cl, Br, I), dihydrogen artemisin radical] are prepared by reaction of dihydrogen artemisin, dihydrogen artemisin acetate, dihydrogen artemisin trifluoroacetate, and anilines with R3 substituted groups, R3 or R3 and R4 substituted phenols, Ph compound, heterocyclic compound or its silicone ether derivs. in the presence of acidic catalyst, boron trifluoride etherate, SnCl4, TiCl4, trifluoroacetic acid, p-Me benzenesulfonic acid, trimethylsilyl triflate, H2SO4 and H3PO4 and polar solvent, alkyl halide, Et ether, acetonitrile, THF, pyridine, triethylamine, and methyl-sulfoxide at -10° to 40°. Phenylamino artemisin, 3-chloro-phenylamino artemisin, 4-artemisin, 3-nitro-phenoxy artemisin, 4- methoxy-phenoxy artemisin, 4-(methoxycarbonyl)-phenoxy artemisin, 4-acetamino-phenoxy artemisin, tris(artemisin) phloroglucin, 5- hydroxy-1,3-bis(artemisin) benzenediol, adenyl artemisin, 5- fluoro-uracil artemisin, 3-aminocarbonyl triazo artemisin, and 2,4- dimethoxyphenyl artemisin were prepared as antitumor, antiviral, and antiparasitic agents.

IT **221890-88-6P 221890-89-7P 221890-90-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of artemisin derivs. as antibiotics and antitumor agents)

RN 221890-88-6 CAPLUS

CN 9H-Purin-6-amine, 9-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221890-89-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-9-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221890-90-0 CAPLUS
CN 1H-1,2,4-Triazole-3-carboxamide, 9-[(3R,5aS,6R,8aS,9R,10R,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Me
R
O
O
O
R
S
Me
O
H
R
H
R
O
N
R
S
H2N
N
R
H
N
Me